BCL2L1 and B-cell chronic lymphocytic leukemia: ABT-263 (navitoclax) was another potent inhibitor of BCL-2, BCL-XL and BCL-w, showing activity in chronic lymphocytic leukemia (CLL), but its clinical development was halted due to dose-limiting severe thrombocytopenia resulting from BCL-XL inhibition [7].